Epigenetic Effects Elicited By Lactobacillus GG In Children With Cow's

Status Recruiting

Clinical Trial Summary

Lactobacillus GG (LGG) is able to exert long lasting effects in children with atopic disorders. We have shown that Nutramigen LGG accelerates tolerance acquisition in infants with cow's milk allergy (CMA). The mechanisms of these effects are still largely undefined. The effect of LGG could be related at least in part by the immunoregulatory role played by LGG. This probiotic can balance the generation of cytokines possibly involved in IgE- or non-IgE-mediated CMA (i.e., IL-4, IL-5, IL-10, IFN-γ , TGF-beta, and TNF-alfa), which can contribute to modulation of inﬂammatory processes. We have demonstrated that children with IgE-mediated CMA produce significantly higher level of IL-4 and IL-13 in response to cow's milk protein, and that tolerance is associated with a marked reduction of IL-13 production and a concomitant increased frequency of IFN-γ releasing cells.

Epigenetics studies the heritable (and potentially reversible) changes of the genome inherited from one cell generation to the next which alter gene expression but do not involve changes in primary DNA sequences, highlighting the complexity of the inter-relationship between genetics and nutrition. There are three distinct, but closely interacting, epigenetic mechanisms (histone acetylation, DNA methylation, and non-coding microRNAs) that are responsible for modifying the expression of critical genes associated with physiologic and pathologic processes. The profile of epigenetic modifications associated with Th lineage commitment, coupled with the sensitivity of the early developmental period, has led to speculation that factors that disrupt these pathways may increase the risk of allergic diseases. Specifically, effects on DNA methylation and endogenous histone deacetylase inhibitors acting on specific pathways (Th1 and T regulatory cell differentiation) may favour Th2-associated allergic differentiation. MicroRNAs are another structural components of an epigenetic mechanism of post-transcriptional regulation of messenger RNA translation. It has been recently identified a specific Th2-associated miRNA (miR-21) that is critical for the regulation of Th cell polarization.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02062476
Study type	Interventional
Source	Federico II University
Contact	Roberto Berni Canani, MD, PhD
Phone	0817462680
Status	Recruiting
Phase	Phase 2
Start date	July 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02738060` - The Effect of Baked Milk on Cow's Milk Allergy	Phase 2
Recruiting	`NCT02149134` - Evaluation of the Efficacy of a New Infant Formula in Subjects With Cow's Milk Allergy	Phase 2
Recruiting	`NCT01891916` - Effect Of Lactobacillus GG on Atopic March	N/A
Completed	`NCT01622426` - Tolerance to a New Free Amino Acid-based Formula in Children With IgE or Non-IgE-mediated Cow's Milk Allergy	N/A
Completed	`NCT01634490` - Effects of Different Dietary Regimens on Tolerance Acquisition in Children With Cow's Milk Allergy	N/A
Completed	`NCT02466035` - Epigenetic Effects Involved in Children With Cow's Milk Allergy (EPICMA)	N/A
Completed	`NCT02379598` - Effect of Therapy With Aminoacid Based Formula Versus Hydrolyzed Whey Proteins in Children With Cow's Milk Allergy	N/A
Completed	`NCT04330092` - Diagnosis of Cow's Milk Protein Allergy
Not yet recruiting	`NCT02081651` - Parmigiano-Reggiano Cheese as a Possible Strategy to Acquire Oral Tolerance in Children With Cow's Milk Allergy	Phase 3
Completed	`NCT03462030` - Baked Milk Oral Immunotherapy for Cow's Milk Allergy	Phase 2
Completed	`NCT02465905` - Oral Immunotherapy in Cow's Milk Allergy (CMA) in Children : "Petit Lait" Study	N/A
Suspended	`NCT05731206` - Hypoallergenicity of a Hydrolyzed Protein Infant Formula	N/A
Not yet recruiting	`NCT06456541` - Infant Formula in Infants and Children With Cow's Milk Allergy	N/A
Completed	`NCT01589731` - Polymerized Beta-lactoglobulin Comparative Immunoreactivity	N/A
Terminated	`NCT02405923` - Growth, Safety and Tolerance of a Rice Protein Hydrolysate Formula in Infants With Cow's Milk Protein Allergy	N/A
Terminated	`NCT04910373` - Extensively Hydrolyzed Infant Formula in Infants and Children With Cow's Milk Allergy	N/A
Recruiting	`NCT01968278` - Use of Baked Milk in Oral Immunotherapy for Severe IgE-mediated Cow's Milk Protein Allergic Patients	N/A
Withdrawn	`NCT01470768` - Evaluation of Fatty Acid Levels and Growth in Infants Fed Amino Acid Based (AA) Formulas	N/A
Recruiting	`NCT05883384` - Validity of Cow's Milk-related Symptom Score Among Children Suspected to Have Cow's Milk Protein Alergy
Completed	`NCT01901380` - Cow's Milk Allergy and Functional Gastrointestinal Disorders	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Epigenetic Effects Elicited By Lactobacillus GG In Children With Cow's Milk Allergy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms